Novaliq Presents Data from Second Phase 3 Trial of Investigati...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
HEIDELBERG, Germany, and CAMBRIDGE, Mass., April 26, 2022 /PRNewswire-AsiaNet/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol(R) water-free technology, today announced that data from the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investiga...
Authors: LATEST ASIANET NEWS RELEASES